|
Idera Pharmaceuticals, Inc. - Sales Analysis Snapshot
Business Description
This Report provides a comprehensive Sales & Margin summary analysis for Idera Pharmaceuticals, Inc. Tabular results include up to a ten-year history on Sales, EBITDA (Earnings before Interest, Taxes, Depreciation and Amortization), Income before Extraordinary Items and number of Employees. Additional ratios are included for sales growth, earnings and income as a percent of sales and Sales per Employee.
Idera Pharmaceuticals, Inc.. The Company's principal activity is discovering and developing novel therapeutics that modulate immune responses through Toll-like Receptors (TLR). TLRs are specific receptors present in immune system cells that direct the immune system to respond to potential disease threats. The Company discovers and develops synthetic DNA- and RNA-based compounds for the treatment of cancer, infectious diseases, autoimmune diseases, and asthma/allergies and for use as vaccine adjuvants. It has three internal programs, in oncology, infectious diseases, and autoimmune diseases and two collaborative alliances relating to the development of treatments for asthma and allergies and the development of adjuvants for vaccines. The Company is currently conducting a Phase 2 trial of IMO-2055 in oncology and a Phase 1/2 trial of IMO-2055 in combination with chemotherapy in oncology. Its trademarks are IMOtm, Idera(R), IMOxine(R) and GEM(R). The Company operates in the United States.
Not the Report you are looking for? Click here for more browsing options.
Layout and Content of a Typical Report
|
